Welcome!

News Feed Item

EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2022

NEW YORK, April 22, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2022

http://www.reportlinker.com/p01163175/EpiCast-Report-Non-Small-Cell-Lung...

EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2022

Summary

Lung cancer is a disease of uncontrolled cell growth in the lung tissues. It is one of the most commonly occurring cancers in the world, representing almost 13% of all cancers (Ferlay et al., 2010). NSCLC is the most common type of lung cancer, comprising about 85% of all lung cancers. An estimated 1.37 million new cases of NSCLC occurred worldwide in 2008 (Ferlay et al., 2010).

This forecast was built on an in-depth analysis of historical trends for lung cancer incidence, mortality, and survival; smoking prevalence, disease stage at diagnosis, and the status of lung cancer screening programs in each market.

GlobalData epidemiologists forecast that the number of incident cases of NSCLC in the 9MM will grow from 1.03 million cases in 2012 to 1.26 million by 2022 at a rate of 2.2% per year. The increase in the number of NSCLS incident cases is driven by changes in the incidence of lung cancer, an aging population, population growth, smoking habits in men and women, and exposure to environmental risk factors. Of the nine markets, China will have the highest number of incident cases of NSCLC, growing from 0.55 million cases in 2012 to 0.69 million by 2022 at a rate of 2.5% per year. In addition to China, India and Japan are also important markets for NSCLC in the next 10 years because these countries have a growing older population, a high smoking prevalence, and few smoking bans compared with western countries.

Scope

- The NSCLC EpiCast Report provides overview of the risk factors and the global and historical trends for NSCLC in the nine major markets (9MM): US, France, Germany, Italy, Spain, UK, Japan, China, and India.

- It also includes a 10-year epidemiology forecast of the diagnosed incident cases of NSCLC in these markets from 2012–2022.

- The incident cases are further segmented by sex and age (40–49 years, 50–59 years, 60–69 years, 70–79 years, and at ages 80 years and older), cancer stage at diagnosis (AJCC Stage I-IV), cancer histological subtype (adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and others), and the proportion of smokers among NSCLC cases.

Reasons to buy

- Develop business strategies by understanding the trends shaping and driving the global NSCLC market.

- Quantify patient populations in the global NSCLC market to improve product development, pricing, and launch plans.

- Organize sales and marketing efforts by identifying sex, age groups, and cancer histological subtypes that present the best opportunities for NSCLC therapeutics in each of the markets covered.

Table of Contents

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 5

2 Introduction 7

2.1 Catalyst 7

2.2 Upcoming Reports 7

3 Epidemiology 8

3.1 Risk Factors and Comorbidities 9

3.1.1 Smokers are more likely to have lung cancer than non-smokers 10

3.1.2 Long-term exposure to radon increases the risk of lung cancer 11

3.1.3 Family history of any cancer increases lung cancer risk 11

3.1.4 TB increases the risk of lung cancer and increases mortality risk 12

3.1.5 COPD is a comorbidity that reduces lung cancer survival 12

3.1.6 Lung cancer screening programs may not be beneficial 13

3.1.7 Stage at diagnosis significantly impacts the survival of lung cancer cases 14

3.2 Global Trends 14

3.2.1 US 18

3.2.2 France 22

3.2.3 Germany 24

3.2.4 Italy 25

3.2.5 Spain 27

3.2.6 UK 29

3.2.7 Japan 30

3.2.8 China 32

3.2.9 India 34

3.3 Forecast Methodology 35

3.3.1 Sources Used 37

3.3.2 Sources Not Used 41

3.3.3 Forecast Methods and Assumptions 42

3.4 Epidemiology Forecast (2012–2022) 44

3.4.1 Incident Cases of NSCLC 44

3.4.2 Age-Specific Incident Cases of NSCLC 46

3.4.3 Sex-Specific Incident Cases of NSCLC 47

3.4.4 Age-Standardized Incidence Rates of NSCLC 48

3.4.5 Segmentation of NSCLC Incident Cases 50

3.5 Discussion 58

3.5.1 Limitations of the Analysis 59

3.5.2 Strengths of the Analysis 59

4 Appendix 61

4.1 Bibliography 61

4.2 About the Authors 69

4.2.1 Epidemiologists 69

4.2.2 Reviewers 70

4.2.3 Global Director of Epidemiology and Clinical Trials Analysis 71

4.2.4 Global Head of Healthcare 71

4.3 About GlobalData 72

4.4 About EpiCast 72

4.5 Contact Us 72

4.6 Disclaimer 73

List of Tables

Table 1: Risk Factors and Comorbidities for Lung Cancer 9

Table 2: 9MM, Age-Standardized (World) Smoking Prevalence, Men and Women, 2006 and 2009 17

Table 3: 9MM, Sources of NSCLC Incidence Data 36

Table 4: 9MM, Incident Cases of NSCLC, Men and Women Ages ?40 Years, N, Selected Years 2012–2022 44

Table 5: 9MM, Incident Cases of NSCLC, by Age, Men and Women, N (Row %), 2012 46

Table 6: 9MM, Incident Cases of NSCLC, by Sex, Ages ?40 Years, N (Row %), 2012 47

Table 7: 9MM, Incident Cases of NSCLC, by Stage at Diagnosis, Men and Women Ages ?40 Years, N (Row %), 2012 51

Table 8: 9MM, Incident Cases of NSCLC, by Histological Subtype, Ages ?40 Years, Men and Women, N (Row %) , 2012 54

Table 9: Comparison of GlobalData Forecast for Lung Cancer Incident Cases with Globocan 2008 60

List of Figures

Figure 1: 9MM, Age-Standardized (World) Lung Cancer Incidence, Men Ages ?40 Years, 1993–2002 15

Figure 2: 9MM, Age-Standardized (World) Lung Cancer Incidence, Women Ages ?40 Years, 1993–2002 16

Figure 3: Age-Standardized (US 2000) Lung Cancer Incidence and Mortality, Men and Women, All Ages, US, 1999–2008 19

Figure 4: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, US, 1993–2008 20

Figure 5: Relative Risk of Death from Lung Cancer in Current Smokers, Men and Women, US 21

Figure 6: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, France, 1993–2008 23

Figure 7: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, Germany, 1993–2008 24

Figure 8: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, Italy, 1993–2008 26

Figure 9: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, Spain, 1991–2007 28

Figure 10: Age-Standardized (World) Lung Cancer Incidence and Mortality, Ages ?40 Years, UK, 1993–2008 29

Figure 11: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, Japan, 1993–2008 31

Figure 12: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, China, 1993–2008 33

Figure 13: Age-Standardized (World) Lung Cancer Incidence, Men and Women Ages ?40 Years, India, 1993–2002 34

Figure 14: 9MM, Incident Cases of NSCLC, Men and Women Ages ?40 Years, N, Selected Years 2012–2022 45

Figure 15: 9MM, Incident Cases of NSCLC, by Sex, Ages ?40 Years, N, 2012 48

Figure 16: 9MM, Age-Standardized (World) NSCLC Incidence, 2012 49

Figure 17: 9MM, Incident Cases of NSCLC, by Stage at Diagnosis, Men and Women Ages ?40 Years, % and N, 2012 52

Figure 18: 9MM, Incident Cases of NSCLC by Histological Subtype, Men and Women Ages ?40 Years, %, 2012 55

Figure 19: 9MM, Proportion of Smokers Among NSCLC Cases and the General Population, Men and Women, %, 2012 56

Figure 20: Smoking History in NSCLC Cases in the 9MM, Men and Women Ages ?40 Years, N, 2012 57

To order this report:Pathology Industry: EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2022

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

 

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
This talk centers around how to automate best practices in a multi-/hybrid-cloud world based on our work with customers like GE, Discovery Communications and Fannie Mae. Today’s enterprises are reaping the benefits of cloud computing, but also discovering many risks and challenges. In the age of DevOps and the decentralization of IT, it’s easy to over-provision resources, forget that instances are running, or unintentionally expose vulnerabilities.
Everywhere we turn in our industry we can find strong opinions about the direction, type and nature of cloud’s impact on computing and business. Another word that is used in every context in our industry is “hybrid.” In his session at 20th Cloud Expo, Alvaro Gonzalez, Director of Technical, Partner and Field Marketing at Peak 10, will use a combination of a few conceptual props and some research recently commissioned by Peak 10 to offer a real-world consideration of how the various categories of...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
In his opening keynote at 20th Cloud Expo, Michael Maximilien, Research Scientist, Architect, and Engineer at IBM, will motivate why realizing the full potential of the cloud and social data requires artificial intelligence. By mixing Cloud Foundry and the rich set of Watson services, IBM's Bluemix is the best cloud operating system for enterprises today, providing rapid development and deployment of applications that can take advantage of the rich catalog of Watson services to help drive insigh...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
When NSA's digital armory was leaked, it was only a matter of time before the code was morphed into a ransom seeking worm. This talk, designed for C-level attendees, demonstrates a Live Hack of a virtual environment to show the ease in which any average user can leverage these tools and infiltrate their network environment. This session will include an overview of the Shadbrokers NSA leak situation.
In his keynote at @ThingsExpo, Chris Matthieu, Director of IoT Engineering at Citrix and co-founder and CTO of Octoblu, focused on building an IoT platform and company. He provided a behind-the-scenes look at Octoblu’s platform, business, and pivots along the way (including the Citrix acquisition of Octoblu).
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deli...
As enterprise cloud becomes the norm, businesses and government programs must address compounded regulatory compliance related to data privacy and information protection. The most recent, Controlled Unclassified Information and the EU’s GDPR have board level implications and companies still struggle with demonstrating due diligence. Developers and DevOps leaders, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by in...
Five years ago development was seen as a dead-end career, now it’s anything but – with an explosion in mobile and IoT initiatives increasing the demand for skilled engineers. But apart from having a ready supply of great coders, what constitutes true ‘DevOps Royalty’? It’ll be the ability to craft resilient architectures, supportability, security everywhere across the software lifecycle. In his keynote at @DevOpsSummit at 20th Cloud Expo, Jeffrey Scheaffer, GM and SVP, Continuous Delivery Busine...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend @CloudExpo | @ThingsExpo, June 6-8, 2017, at the Javits Center in New York City, NY and October 31 - November 2, 2017, Santa Clara Convention Center, CA. Learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
SYS-CON Events announced today that EARP Integration will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. EARP Integration is a passionate software house. Since its inception in 2009 the company successfully delivers smart solutions for cities and factories that start their digital transformation. EARP provides bespoke solutions like, for example, advanced enterprise portals, business intelligence systems an...
SYS-CON Events announced today that WineSOFT will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Based in Seoul and Irvine, WineSOFT is an innovative software house focusing on internet infrastructure solutions. The venture started as a bootstrap start-up in 2010 by focusing on making the internet faster and more powerful. WineSOFT’s knowledge is based on the expertise of TCP/IP, VPN, SSL, peer-to-peer, mob...
SYS-CON Events announced today that delaPlex will exhibit at SYS-CON's @CloudExpo, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. delaPlex pioneered Software Development as a Service (SDaaS), which provides scalable resources to build, test, and deploy software. It’s a fast and more reliable way to develop a new product or expand your in-house team.